35
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Clinical Diagnosis of Progressive Supranuclear Palsy: The Movement Disorder Society Criteria

      research-article
      , MD 1 , 2 , , MD 1 , 2 , , MD 3 , , MD 4 , , MD, MST, MSc 5 , , MD 6 , , MD 7 , , MD 8 , , MD 9 , , PhD 10 , , MD 2 , 4 , 11 , , MD 12 , , MD 13 , , MD 11 , , MD 14 , , MD, PhD 15 , 16 , 17 , , MD 18 , , MD 19 , , MD 20 , , PhD, MSc 21 , , MD 22 , , MD 23 , , MD, PhD 24 , , MD, PhD 25 , , MD, PhD 26 , , MD, FEAN 27 , , MD 28 , , MD 29 , , MD 19 , , MD 14 , , MD 30 , , MD, PhD 31 , , MD 2 , 32 , , MD 33 , 34 , 35 , , MD 36 , , MD 37 , , MD 38 , , MD 31 , , MD 39 , , MD 40 , , PhD 41 , , MD 31 , , MD 42 , , MD, PhD 31 , , MD, PhD 39 , , MD 43 , , MD 44
      Movement disorders : official journal of the Movement Disorder Society
      progressive supranuclear palsy, evidence-based, consensus-based, clinical diagnostic criteria

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          PSP is a neuropathologically defined disease entity. Clinical diagnostic criteria, published in 1996 by the National Institute of Neurological Disorders and Stroke/Society for PSP, have excellent specificity, but their sensitivity is limited for variant PSP syndromes with presentations other than Richardson’s syndrome.

          Objective

          We aimed to provide an evidence- and consensus-based revision of the clinical diagnostic criteria for PSP.

          Methods

          We searched the PubMed, Cochrane, Medline, and PSYCInfo databases for articles published in English since 1996, using postmortem diagnosis or highly specific clinical criteria as the diagnostic standard. Second, we generated retrospective standardized clinical data from patients with autopsy-confirmed PSP and control diseases. On this basis, diagnostic criteria were drafted, optimized in two modified Delphi evaluations, submitted to structured discussions with consensus procedures during a 2-day meeting, and refined in three further Delphi rounds.

          Results

          Defined clinical, imaging, laboratory, and genetic findings serve as mandatory basic features, mandatory exclusion criteria, or context-dependent exclusion criteria. We identified four functional domains (ocular motor dysfunction, postural instability, akinesia, and cognitive dysfunction) as clinical predictors of PSP. Within each of these domains, we propose three clinical features that contribute different levels of diagnostic certainty. Specific combinations of these features define the diagnostic criteria, stratified by three degrees of diagnostic certainty (probable PSP, possible PSP, and suggestive of PSP). Clinical clues and imaging findings represent supportive features.

          Conclusions

          Here, we present new criteria aimed to optimize early, sensitive, and specific clinical diagnosis of PSP on the basis of currently available evidence.

          Related collections

          Most cited references36

          • Record: found
          • Abstract: found
          • Article: not found

          Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders.

          As there are no biological markers for the antemortem diagnosis of degenerative parkinsonian disorders, diagnosis currently relies upon the presence and progression of clinical features and confirmation depends on neuropathology. Clinicopathologic studies have shown significant false-positive and false-negative rates for diagnosing these disorders, and misdiagnosis is especially common during the early stages of these diseases. It is important to establish a set of widely accepted diagnostic criteria for these disorders that may be applied and reproduced in a blinded fashion. This review summarizes the findings of the SIC Task Force for the study of diagnostic criteria for parkinsonian disorders in the areas of Parkinson's disease, dementia with Lewy bodies, progressive supranuclear palsy, multiple system atrophy, and corticobasal degeneration. In each of these areas, diagnosis continues to rest on clinical findings and the judicious use of ancillary studies. Copyright 2003 Movement Disorder Society
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy).

            We present the preliminary neuropathologic criteria for progressive supranuclear palsy (PSP) as proposed at a workshop held at the National Institutes of Health, Bethesda, MD, April 24 and 25, 1993. The criteria distinguish typical, atypical, and combined PSP. A semiquantitative distribution of neurofibrillary tangles is the basis for the diagnosis of PSP. A high density of neurofibrillary tangles and neuropil threads in the basal ganglia and brain-stem is crucial for the diagnosis of typical PSP. Tau-positive astrocytes or their processes in areas of involvement help to confirm the diagnosis. Atypical cases of PSP are variants in which the severity or distribution of abnormalities deviates from the typical pattern. Criteria excluding the diagnosis of typical and atypical PSP are large or numerous infarcts, marked diffuse or focal atrophy, Lewy bodies, changes diagnostic of Alzheimer's disease, oligodendroglial argyrophilic inclusions, Pick bodies, diffuse spongiosis, and prion protein-positive amyloid plaques. The diagnosis of combined PSP is proposed when other neurologic disorders exist concomitantly with PSP.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism.

              The clinical diagnosis of progressive supranuclear palsy (PSP) relies on the identification of characteristic signs and symptoms. A proportion of pathologically diagnosed cases do not develop these classic features, prove difficult to diagnose during life and are considered as atypical PSP. The aim of this study was to examine the apparent clinical dichotomy between typical and atypical PSP, and to compare the biochemical and genetic characteristics of these groups. In 103 consecutive cases of pathologically confirmed PSP, we have identified two clinical phenotypes by factor analysis which we have named Richardson's syndrome (RS) and PSP-parkinsonism (PSP-P). Cases of RS syndrome made up 54% of all cases, and were characterized by the early onset of postural instability and falls, supranuclear vertical gaze palsy and cognitive dysfunction. A second group of 33 (32%) were characterized by asymmetric onset, tremor, a moderate initial therapeutic response to levodopa and were frequently confused with Parkinson's disease (PSP-P). Fourteen cases (14%) could not be separated according to these criteria. In RS, two-thirds of cases were men, whereas the sex distribution in PSP-P was even. Disease duration in RS was significantly shorter (5.9 versus 9.1 years, P < 0.001) and age at death earlier (72.1 versus 75.5 years, P = 0.01) than in PSP-P. The isoform composition of insoluble tangle-tau isolated from the basal pons also differed significantly. In RS, the mean four-repeat:three-repeat tau ratio was 2.84 and in PSP-P it was 1.63 (P < 0.003). The effect of the H1,H1 PSP susceptibility genotype appeared stronger in RS than in PSP-P (odds ratio 13.2 versus 4.5). The difference in genotype frequencies between the clinical subgroups was not significant. There were no differences in apolipoprotein E genotypes. The classic clinical description of PSP, which includes supranuclear gaze palsy, early falls and dementia, does not adequately describe one-third of cases in this series of pathologically confirmed cases. We propose that PSP-P represents a second discrete clinical phenotype that needs to be clinically distinguished from classical PSP (RS). The different tau isoform deposition in the basal pons suggests that this may ultimately prove to be a discrete nosological entity.
                Bookmark

                Author and article information

                Journal
                8610688
                5937
                Mov Disord
                Mov. Disord.
                Movement disorders : official journal of the Movement Disorder Society
                0885-3185
                1531-8257
                26 May 2017
                03 May 2017
                June 2017
                01 June 2018
                : 32
                : 6
                : 853-864
                Affiliations
                [1 ]Department of Neurology, Technische Universitat Munchen, Munich, Germany
                [2 ]German Center for Neurodegenerative Diseases (DZNE), Munich, Germany
                [3 ]Second Department of Neurology, Attikon University Hospital, University of Athens, Athens, Greece
                [4 ]Department of Psychiatry, Ludwig-Maximilians-Universitat, Munich, Germany
                [5 ]Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA
                [6 ]Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J. Safra Program in Parkinson’s Disease, Toronto Western Hospital, Toronto, Canada
                [7 ]Paracelsus-Elena Klinik, Kassel, Germany, and University Medical Center Gottingen, Institute of Neuropathology, Gottingen, Germany
                [8 ]Institute of Human Genetics, Giessen, Germany
                [9 ]Department of Clinical Sciences, Division of Neurology, Lund University, Lund, Sweden
                [10 ]Department of Radiology, Mayo Clinic, Rochester, Minnesoya, USA
                [11 ]Center for Neuropathology and Prion Research, Ludwig-Maximilians-Universitat, Munich, Germany
                [12 ]Department of Clinical Sciences, Division of Oncology and Pathology, Lund University, Lund, Sweden
                [13 ]Neurological Tissue Bank of the Biobank - Hospital Clínic de Barcelona, Universitat de Barcelona, IDIBAPS, Barcelona, Spain
                [14 ]Frontotemporal Degeneration Center, Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
                [15 ]Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France
                [16 ]CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France
                [17 ]Service de Neurologie, Hôpital Pellegrin, CHU de Bordeaux, Bordeaux, France
                [18 ]Department of Neurology, Johns Hopkins University, Baltimore, Maryland, USA
                [19 ]Division of Neurology, Royal University Hospital, University of Saskatchewan, Saskatoon, SK, Canada
                [20 ]Department of Neurology, Erasmus Medical Centre, Rotterdam, The Netherlands
                [21 ]London Neurodegenerative Diseases Brain Bank, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, London, United Kingdom
                [22 ]Parkinson and Movement Disorders Unit, IRCCS Hospital San Camillo, Venice, and Department of Neurosciences, Padova University, Padova, Italy
                [23 ]Sobell Department of Motor Neuroscience and Movement Disorders, UCL Institute of Neurology, Queen Square, London, United Kingdom
                [24 ]Department of Neurology, University of California, Los Angeles, California, USA
                [25 ]Parkinson’s Disease & Movement Disorders Unit, Neurology Service, Hospital Clinic/IDIBAPS/University of Barcelona, Barcelona, Catalonia, Spain
                [26 ]Sorbonne Universités, UPMC Univ Paris 06; and INSERM UMRS_1127, CIC_1422; and CNRS UMR_7225; and AP-HP; and ICM, Hôpital Pitié-Salpêtrière, Département des maladies du système nerveux, Paris, France
                [27 ]Department of Neurology, Santa Maria University Hospital of Terni, Terni, Italy
                [28 ]Mayo Clinic, Jacksonville, Florida, USA
                [29 ]Department of Geriatric Medicine, University Hospital Essen, Essen, Germany
                [30 ]Department of Neurology, University of Ulm, Ulm, Germany
                [31 ]Department of Neurology, Medical University Innsbruck, Innsbruck, Austria
                [32 ]Department of Neurology, Ludwig-Maximilians-Universitat, Munich, Germany
                [33 ]Institute of Nursing Science and Practice, Paracelsus Medical University, Salzburg, Austria
                [34 ]Department of Neurology, Hospital Agatharied, Agatharied, Germany
                [35 ]Department of Palliative Medicine, Munich University Hospital, LMU Munich, Munich, Germany
                [36 ]Department of Clinical Neuroscience, UCL Institute of Neurology, London, United Kingdom
                [37 ]German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany
                [38 ]Department of Neurology, Philipps Universitat, Marburg, Germany
                [39 ]Memory and Aging Center, Department of Neurology, University of California, San Francisco, California, USA
                [40 ]Department of Clinical Neurosciences, Cambridge University, Cambridge, United Kingdom
                [41 ]Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
                [42 ]Departments of Nuclear Medicine and Neurology, University of Cologne, Cologne, Germany
                [43 ]Department of Neurology, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA
                [44 ]Department of Neurology, University of California, San Diego, California, USA
                Author notes
                [* ]Correspondence to: Prof. Dr. Gunter U. Hoglinger, Department of Translational Neurodegeneration, German Center for Neurodegenerative Diseases (DZNE), Feodor-Lynen Straβe 17, D-81677 Munich, Germany; guenter.hoeglinger@ 123456dzne.de

                Drs. Hoglinger, Respondek, Stamelou, Golbe, Boxer, and Litvan made an equal contribution.

                Article
                PMC5516529 PMC5516529 5516529 nihpa879447
                10.1002/mds.26987
                5516529
                28467028
                ada4eb24-e8b7-4696-984f-f0ccbcde0106
                History
                Categories
                Article

                progressive supranuclear palsy,evidence-based,consensus-based,clinical diagnostic criteria

                Comments

                Comment on this article